Andrew K. Godwin, PhD

Deputy Director, The University of Kansas Cancer Center
Director, Biospecimen Repository, The University of Kansas Cancer Center
Chancellor’s Distinguished Chair in Biomedical Sciences Professor
Professor, Department of Pathology and Laboratory Medicine, The University of Kansas School of Medicine
Director, Molecular Oncology, The University of Kansas Medical Center
Biorepository Coordinator for the HICTR Translational Technologies Resource Center
Kansas Bioscience Authority Eminent Scholar

Andrew Godwin

Andrew K. Godwin, Ph.D. is a leader in the field of translational research and personalized cancer medicine. Dr. Godwin was recruited to the KU Cancer Center in late 2010 where he served as associate director for Translational Research for nearly three years.  He was appointed deputy director of The University of Kansas Cancer Center in May 2013 and currently serves as director of the cancer center’s Biospecimen Repository, professor of Pathology and Laboratory Medicine, and director of Molecular Oncology at the University of Kansas Medical Center. He was named a Kansas Bioscience Authority Eminent Scholar in 2010 and the University of Kansas School of Medicine Chancellor’s Distinguished Chair in Biomedical Sciences Endowed Professor in 2012.

Dr. Godwin is a National Cancer Institute (NCI)-funded investigator since 1993 and a highly published and cited scientist with more than 300 publications. He is internationally recognized for his molecular biology/genetic studies of gastrointestinal stromal tumors, breast and ovarian cancer, and his efforts to help bridge the gap between basic and clinical science in order to improve patient care. 

His research focuses on the concept of obtaining a molecular definition of a tumor to define its treatment-sensitive elements, complementing his long-standing interest in the fields of cancer genetics, molecular targeted therapeutics, predictive biomarkers, early detection and biobanking.

Dr. Godwin co-leads the ovarian cancer working group at the KU Cancer Center and has served as the translational science co-chair or collaborating scientist for many Gynecologic Oncology Group (GOG) clinical trials evaluating molecularly targeted agents in recurrent ovarian cancer patients, and as a member of the experimental therapeutic committee of Eastern Cooperative Oncology Group (ECOG). He is a member of NCI’s Early Detection Research Network (EDRN), an initiative to discover and validate biomarkers for early detection of cancer, and the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), an international group that evaluates large cohorts of BRCA1 and BRCA2 mutation carriers for genetic modifiers of breast and ovarian cancer risk. He has served on numerous editorial boards and grant peer-review panels, including those for the American Cancer Society, the National Institutes of Health, the U.S. Army Medical Research and Materiel Command, the Mary Kay Foundation and the Susan G. Komen Foundation, and is a member of numerous External Scientific Advisory Boards.

A native of Lawrence, Kan., Dr. Godwin graduated with highest distinction from the University of Kansas with a Bachelor of Science degree in Biology. He obtained his Ph.D. in Molecular Biology from the University of Pennsylvania while carrying out his thesis research at Fox Chase Cancer Center (FCCC) in Philadelphia. At FCCC, he achieved the rank of Senior Member and held the positions of co-leader of the Women's Cancer Program, co-PI of the Ovarian Cancer SPORE, and director of both the Clinical Molecular Genetics Laboratory and the Biosample Repository.

Clinical Trials

Medical research finds ways to help people live longer, improve their quality of life and manage or cure disease. This is possible because of the people who volunteer to participate in clinical trials.

Learn more about clinical trials »
View clinical trials »